RT Journal Article
SR Electronic
T1 Antibody and T cell responses to Sinopharm/BBIBP-CorV in naïve and previously infected individuals in Sri Lanka
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.15.21260621
DO 10.1101/2021.07.15.21260621
A1 Jeewandara, Chandima
A1 Aberathna, Inoka Sepali
A1 Pushpakumara, Pradeep Darshana
A1 Kamaladasa, Achala
A1 Guruge, Dinuka
A1 Jayathilaka, Deshni
A1 Gunasekara, Banuri
A1 Tanussiya, Shyrar
A1 Kuruppu, Heshan
A1 Ranasinghe, Thushali
A1 Dayarathne, Shashika
A1 Dissanayake, Osanda
A1 Gamalath, Nayanathara
A1 Ekanayake, Dinithi
A1 Jayamali, MPDJ
A1 Wijesinghe, Ayesha
A1 Dissanayake, Madushika
A1 Madusanka, Deshan
A1 Jayadas, Tibutius Thanesh
A1 Mudunkotuwa, Anushika
A1 Somathilake, Gayasha
A1 Harvie, Michel
A1 Nimasha, Thashmi
A1 Danasekara, Saubhagya
A1 Wijayamuni, Ruwan
A1 Schimanski, Lisa
A1 Tan, Tiong K.
A1 Dong, Tao
A1 Townsend, Alain
A1 Ogg, Graham S.
A1 Malavige, Gathsaurie Neelika
YR 2021
UL http://medrxiv.org/content/early/2021/07/19/2021.07.15.21260621.abstract
AB Background As there are limited data of the immunogenicity of the Sinopharm/BBIBP-CorV in different populations, antibody responses against different SARS-CoV-2 variants of concern and T cell responses, we investigated the immunogenicity of the vaccine, in individuals in Sri Lanka.Methods SARS-CoV-2-specific antibodies were measured in 282 individuals who were seronegative at baseline, and ACE2 receptor blocking antibodies, antibodies to the receptor binding domain (RBD) of the wild type (WT), B.1.1.7, B.1.351 and B.1.617.2, ex vivo and cultured IFNγ ELISpot assays, intracellular cytokine secretion assays and B cell ELISpot assays were carried out in a sub cohort of the vaccinees at 4 weeks and at 6 weeks (2 weeks after the second dose).Results 95% of the vaccinees seroconverted, although the seroconversion rates were significantly lower (p<0.001) in individuals >60 years (93.3%) compared to those who were 20 to 39 years (98.9%). 81.25% had ACE2 receptor blocking antibodies at 6 weeks, and there was no difference in these antibody titres in vaccine sera compared to convalescent sera (p=0.44). Vaccinees had significantly less (p<0.0001) antibodies to the RBD of WT and B.1.1.7, although there was no difference in antibodies to the RBD of B.1.351 and B.1.617.2 compared to convalescent sera. 27.7% of 46.4% of vaccinees had ex vivo IFNγ and cultured ELISpot responses respectively, and IFNγ and CD107a responses were detected by flow cytometry.Conclusions Sinopharm/BBIBP-CorV appeared to induce high seroconversion rates and induce a similar level of antibody responses against ACE2 receptor, B.1.617.2 and B.1.351 as seen following natural infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful to the World Health Organization, UK Medical Research Council and the Foreign and Commonwealth Office for support. T.K.T. is funded by the Townsend-Jeantet Charitable Trust (charity number 1011770) and the EPA Cephalosporin Early Career Researcher Fund. A.T. are funded by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the Ethics Review Committee of the University of Sri Jayewardenepura, Sri Lanka.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the manuscript, figures and all supporting information files.